Final ACTT-1: Remdesivir Results

摘要

The drug reduced time to recovery among hospitalized patients with COVID-19 who had lower respiratory tract infection. In May 2020, preliminary results of the National Institutes of Health-sponsored Adaptive COVID-19 Treatment Trial (ACTT-1) were published (NEJM JW Infect Dis Aug 2020 and N Engl J Med 2020 May 22; [e-pub]). At that time, not all participants had finished the trial. Now the final results after complete follow-up are published.